Active Surveillance is often the best treatment choice for men with low-risk disease, but new thinking proposes that men with a favorable type of intermediate risk disease may also be candidates for this noninvasive management protocol. Laurence Klotz, MD, the leading expert in active surveillance, addresses this new thinking in this article.

We are excited to bring you information about the latest advancements in prostate cancer care. This issue is packed with helpful information explaining landmark studies in the prostate cancer field...

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Prostatepedia spoke with Dr. Charles G. Drake at length about current trends in immunotherapy for prostate cancer. Here is the interview:

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Mr. Jeff Lee, a mobile technology veteran, develops clinical trial apps for most major pharmaceutical companies. Prostatepedia spoke with him about how mobile technology streamlines the clinical trial experience for both patients and researchers alike. Here is the interview:

Yes, the PCRI Conference is a community or a village of people coming together to share the latest thoughts and ideas on how to deal with prostate cancer. And this, my friends, provides the ultimate calming effect; not only meeting others like you but also empowering each other with more knowledge and friendships and ultimately more solutions and peace of mind.

The 2017 Moyad + Scholz Mid-Year Update was an incredible and enlightening experience. Conferences hosted by the PCRI are created to provide education, empowerment, and support for all attendees. This year, patients and caregivers came together to learn the most recent, accurate information on prostate cancer, have the opportunity to ask questions directly to speakers, and find a peaceful environment to interact with others who understand their situation.

Per the NCCN guidelines, the treatment options for High-Risk prostate cancer are surgery, beam radiation, or a combination of beam radiation plus radioactive seeds. Hormonal therapy (with Lupron for example) is usually given along with the radiation for two to three years. But patients certainly wonder if one of these three treatment options is better than the other two. A study published recently in the October 2016 issue New England Journal of Medicine compared surgery and beam radiation prospectively in men with mostly Low-Risk prostate cancer. It showed equivalent survival rates. A prospective study for High-Risk prostate cancer, however, is unavailable. Only retrospective studies are available.

Focal therapy is a treatment option for men with specific types of localized disease. This treatment attempts to ablate areas of the prostate that contain cancer, while sparing healthy tissue. This article covers both technical and practical information about HIFU.

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals LLC (“Dendreon”) today announced the close of a transaction in which Sanpower Group, a private Chinese conglomerate, acquired Dendreon from an affiliate of Valeant Pharmaceuticals International, Inc. for $819.9 million in cash.

Donate with Charles "Snuffy" Myers today and help PCRI continue their lifesaving mission.